Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
GASC
MCID: GST053
MIFTS: 85

Gastric Cancer (GASC)

Categories: Blood diseases, Cancer diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Gastric Cancer

About this section

MalaCards integrated aliases for Gastric Cancer:

Name: Gastric Cancer 57 12 53 74 37 55
Stomach Cancer 12 75 53 74 29 43 15
Stomach Carcinoma 12 53 15 72
Gastric Carcinoma 12 55 17
Malignant Tumor of Lesser Curve of Stomach 12 72
Malignant Neoplasm of Body of Stomach 12 72
Malignant Neoplasm of Stomach 72 33
Stomach Neoplasms 44 72
Malignant Neoplasm of Lesser Curve of Stomach 12
Malignant Tumor of Greater Curve of Stomach 12
Malignant Tumor of Body of Stomach 12
Ca Greater Curvature of Stomach 12
Ca Lesser Curvature - Stomach 12
Gastric Cancer Intestinal 74
Gastric Cancer, Somatic 57
Adult Stomach Carcinoma 53
Cancer of the Stomach 12
Carcinoma of Stomach 12
Adult Stomach Cancer 53
Gastric Carcinomas 15
Ca Body - Stomach 12
Gastric Neoplasm 12
Stomach Neoplasm 17
Gastric Cancers 15
Cancer, Gastric 40
Gasc 74

Characteristics:

HPO:

32
gastric cancer:
Inheritance somatic mutation


Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Gastrointestinal diseases Immune diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:10534 DOID:5517
OMIM 57 613659
KEGG 37 H00018
MeSH 44 D013274
UMLS 72 C0024623 C0038356 C0153421 more
Sources

Summaries for Gastric Cancer

About this section
NIH Rare Diseases : 53 Stomach cancer, also called gastric cancer, is a form of cancer that occurs due to abnormal and uncontrolled cell growth in the stomach. Most people with early stomach cancer have no signs or symptoms of the condition. In advanced stages, symptoms may include indigestion; nausea and vomiting; difficulty swallowing; feeling full after eating small amounts of food; loss of appetite; vomiting blood; fatigue; and/or weight loss. Most cases of stomach cancer occur sporadically in people with little to no family history of the condition; however, approximately 10% of stomach cancers are considered "familial." Although the underlying cause of some familial cases is unknown, genetic changes (mutations) are identified in a subset of people affected by stomach cancer. Hereditary cancer syndromes associated with a predisposition to stomach cancer include hereditary diffuse gastric cancer, Lynch syndrome, Li-Fraumeni syndrome, familial adenomatous polyposis, and Peutz-Jeghers syndrome. In other families, a cluster of stomach cancers may be due to a combination of gene(s) and/or other shared factors such as environment and lifestyle. The best treatment options for stomach cancer depend on many factors including the stage of the condition and may include surgery, chemotherapy, radiation therapy, and/or targeted therapy (such as monoclonal antibody therapy).

MalaCards based summary : Gastric Cancer, also known as stomach cancer, is related to gastric adenocarcinoma and colorectal cancer, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Gastric Cancer is APC (APC Regulator Of WNT Signaling Pathway), and among its related pathways/superpathways are Gastric cancer and PI3K-Akt signaling pathway. The drugs Aspirin and Pravastatin have been mentioned in the context of this disorder. Affiliated tissues include lymph node, liver and testes, and related phenotypes are stomach cancer and increased level of l-fucose in urine

Disease Ontology : 12 A gastrointestinal system cancer that is located in the stomach.

OMIM : 57 In a review article on the genetic predisposition to gastric cancer, Bevan and Houlston (1999) concluded that several genes may be associated with an increased risk of gastric cancer. Gastric cancer is a manifestation of a number of inherited cancer predisposition syndromes, including hereditary nonpolyposis colon cancer (HNPCC1; see 120435), familial adenomatous polyposis (FAP; 175100), Peutz-Jeghers syndrome (PJS; 175200), Cowden disease (CD; 158350), and the Li-Fraumeni syndrome (151623). See also hereditary diffuse gastric cancer (HDGC; 137215). Canedo et al. (2007) provided a review of genetic susceptibility to gastric cancer in patients infected with Helicobacter pylori (see 600263). (613659)

MedlinePlus : 43 The stomach is an organ between the esophagus and the small intestine. It mixes food with stomach acid and helps digest protein. Stomach cancer mostly affects older people - two-thirds of people who have it are over age 65. Your risk of getting it is also higher if you Have had a Helicobacter pylori infection Have had stomach inflammation Are a man Eat lots of salted, smoked, or pickled foods Smoke cigarettes Have a family history of stomach cancer It is hard to diagnose stomach cancer in its early stages. Indigestion and stomach discomfort can be symptoms of early cancer, but other problems can cause the same symptoms. In advanced cases, there may be blood in your stool, vomiting, unexplained weight loss, jaundice, or trouble swallowing. Doctors diagnose stomach cancer with a physical exam, blood and imaging tests, an endoscopy, and a biopsy. Because it is often found late, it can be hard to treat stomach cancer. Treatment options include surgery, chemotherapy, radiation or a combination. NIH: National Cancer Institute

KEGG : 37
Gastric cancer (GC) is one of the world's most common cancers. According to Lauren's histological classification gastric cancer is divided into two distinct histological groups - the intestinal and diffuse types. Several genetic changes have been identified in intestinal-type GC. The intestinal metaplasia is characterized by mutations in p53 gene, reduced expression of retinoic acid receptor beta (RAR-beta) and hTERT expression. Gastric adenomas furthermore display mutations in the APC gene, reduced p27 expression and cyclin E amplification. In addition, amplification and overexpression of c-ErbB2, reduced TGF-beta receptor type I (TGFBRI) expression and complete loss of p27 expression are commonly observed in more advanced GC. The main molecular changes observed in diffuse-type GCs include loss of E-cadherin function by mutations in CDH1and amplification of MET and FGFR2F.

UniProtKB/Swiss-Prot : 74 Gastric cancer: A malignant disease which starts in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. The term gastric cancer or gastric carcinoma refers to adenocarcinoma of the stomach that accounts for most of all gastric malignant tumors. Two main histologic types are recognized, diffuse type and intestinal type carcinomas. Diffuse tumors are poorly differentiated infiltrating lesions, resulting in thickening of the stomach. In contrast, intestinal tumors are usually exophytic, often ulcerating, and associated with intestinal metaplasia of the stomach, most often observed in sporadic disease.

Wikipedia : 75 Stomach cancer, also known as gastric cancer, is a cancer that develops from the lining of the stomach.... more...

Sources

Related Diseases for Gastric Cancer

About this section

Diseases in the Gastric Cancer family:

Hereditary Gastric Cancer

Diseases related to Gastric Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1249)
# Related Disease Score Top Affiliating Genes
1 gastric adenocarcinoma 35.2 PIK3CA KRAS FGFR2 ERBB2 CTNNB1 APC
2 colorectal cancer 34.2 PIK3CA MUTYH MIR93 MIR34A MIR25 MIR221
3 adenocarcinoma 34.0 PIK3CA KRAS FGFR2 ERBB2 CTNNB1 APC
4 breast cancer 33.7 PIK3CA MIR34A MIR222 MIR221 MIR21 MIR20A
5 hepatocellular carcinoma 33.6 PIK3CA MIR93 MIR34A MIR25 MIR222 MIR221
6 esophageal cancer 33.5 PIK3CA MIR34A MIR21 KRAS ERBB2 CTNNB1
7 pancreatic cancer 33.4 PIK3CA MIR34A MIR25 MIR222 MIR221 MIR21
8 adenoma 33.3 MUTYH KRAS CTNNB1 APC
9 lung cancer 33.2 PIK3CA MIR93 MIR34A MIR222 MIR221 MIR21
10 prostate cancer 33.1 PIK3CA MIR34A MIR25 MIR222 MIR221 MIR21
11 lung cancer susceptibility 3 33.0 PIK3CA KRAS KLF6 ERBB2 CTNNB1 APC
12 familial adenomatous polyposis 32.9 MUTYH KRAS CTNNB1 APC
13 ovarian cancer 32.7 PIK3CA MIR222 MIR221 MIR21 MIR145 MIR106B
14 glioblastoma 32.7 PIK3CA MIR34A MIR25 MIR222 MIR221 MIR21
15 lynch syndrome 32.7 MUTYH KRAS CTNNB1 APC
16 bladder cancer 32.7 MIR222 MIR221 MIR21 MIR145 KRAS ERBB2
17 endometrial cancer 32.6 PIK3CA MUTYH KRAS FGFR2 ERBB2 CTNNB1
18 gastrointestinal system cancer 32.6 PIK3CA MUTYH KRAS ERBB2 CTNNB1
19 colorectal adenoma 32.5 MUTYH KRAS CTNNB1 APC
20 cholangiocarcinoma 32.5 PIK3CA MIR21 KRAS ERBB2 CTNNB1
21 glioma 32.5 PIK3CA MIR34A MIR25 MIR222 MIR221 MIR21
22 cervical cancer 32.4 PIK3CA MIR21 MIR196B IRF1 ERBB2 CTNNB1
23 large intestine cancer 32.4 PIK3CA MUTYH KRAS ERBB2 CTNNB1 APC
24 dermatomyositis 32.3 MIR222 MIR221 MIR21
25 glioblastoma multiforme 32.2 PIK3CA MIR221 MIR21 ERBB2
26 intrahepatic cholangiocarcinoma 32.1 KRAS FGFR2 CTNNB1
27 myeloma, multiple 32.1 MIR93 MIR25 MIR106B KRAS
28 squamous cell carcinoma, head and neck 31.9 PIK3CA MIR221 MIR21 ERBB2 CTNNB1
29 intestinal disease 31.9 PIK3CA MUTYH KRAS CTNNB1
30 pancreatic ductal adenocarcinoma 31.8 MIR93 MIR221 MIR21 MIR145
31 medulloblastoma 31.8 PIK3CA MIR34A MIR20A ERBB2 CTNNB1 APC
32 gastrointestinal system disease 31.8 KRAS ERBB2 CTNNB1
33 carcinosarcoma 31.8 PIK3CA KRAS ERBB2 CTNNB1
34 kidney cancer 31.8 MIR21 MIR20A MIR106B
35 respiratory system cancer 31.8 PIK3CA KRAS ERBB2 CTNNB1
36 thyroid cancer, nonmedullary, 1 31.7 MIR34A MIR222 MIR221
37 adenoid cystic carcinoma 31.7 PIK3CA KRAS ERBB2 CTNNB1
38 esophagus adenocarcinoma 31.5 MIR21 MIR145 ERBB2
39 desmoid tumor 31.5 CTNNB1 APC
40 leukemia, acute lymphoblastic 31.4 MIR222 MIR221 MIR21 MIR196B
41 polymyositis 31.3 MIR222 MIR21
42 attenuated familial adenomatous polyposis 31.3 MUTYH APC
43 familial adenomatous polyposis 1 31.2 CTNNB1 APC
44 polyposis syndrome, hereditary mixed, 1 31.2 MUTYH APC
45 breast adenocarcinoma 30.7 PIK3CA KRAS ERBB2
46 gastric cancer, hereditary diffuse 13.0
47 diffuse gastric cancer 12.7
48 microinvasive gastric cancer 12.6
49 stomach carcinoma in situ 12.5
50 hereditary gastric cancer 12.4

Comorbidity relations with Gastric Cancer via Phenotypic Disease Network (PDN): (show all 11)


Active Peptic Ulcer Disease Acute Cystitis
Deficiency Anemia Gastric Fundus Cancer
Heart Disease Intestinal Obstruction
Iron Deficiency Anemia Neutropenia
Protein-Energy Malnutrition Pylorus Cancer
Stomach Carcinoma in Situ

Graphical network of the top 20 diseases related to Gastric Cancer:



Diseases related to Gastric Cancer
Sources

Symptoms & Phenotypes for Gastric Cancer

About this section

Human phenotypes related to Gastric Cancer:

32
# Description HPO Frequency HPO Source Accession
1 stomach cancer 32 HP:0012126
2 increased level of l-fucose in urine 32 HP:0410067

Clinical features from OMIM:

613659

UMLS symptoms related to Gastric Cancer:


nausea and vomiting, constipation, abdominal pain, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas

MGI Mouse Phenotypes related to Gastric Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 integument MP:0010771 9.56 APC CTNNB1 ERBB2 FGFR2 IRF1 KLF6
2 neoplasm MP:0002006 9.23 APC CTNNB1 ERBB2 FGFR2 IRF1 KRAS
Sources

Drugs & Therapeutics for Gastric Cancer

About this section

DrugBank drugs 16 :

(show all 7)
# Drug Name Indication DrugBank ID
1 Capecitabine For the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen. May also be used in combination with docetaxel for the treatment of metastatic breast cancer in patients who have failed to respond to, or recurred or relasped during or following anthracycline-containing chemotherapy. Capecitabine is used alone as an adjuvant therapy following the complete resection of primary tumor in patients with stage III colon cancer when monotherapy with fluroprymidine is preferred. The use or capecitabine in combination regimens for advanced gastric cancer is currently being investigated. DB01101
2 Cisplatin For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer. DB00515
3 Doxorubicin Doxorubicin is used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms’ tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin’s disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer. DB00997
4 Fluorouracil For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid. DB00544
5 Irinotecan For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. DB00762
6 Oxaliplatin Used in combination with infusional 5-FU/LV, is indicated for the treatment of advanced carcinoma of the colon or rectum and for adjuvant treatment of stage III colon cancer patients who have undergone complete resection of the primary tumor. DB00526
7 Paclitaxel Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer. DB01229

Drugs for Gastric Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 570)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
2
Pravastatin Approved Phase 4 81093-37-0 54687
3
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
4
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
5
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
6
Etomidate Approved Phase 4 33125-97-2 36339 667484
7
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
8
Simethicone Approved Phase 4 8050-81-5
9
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
10
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
11
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
12
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
13
Pantoprazole Approved Phase 4 102625-70-7 4679
14
Morphine Approved, Investigational Phase 4 57-27-2 5288826
15
Coal tar Approved Phase 4 8007-45-2
16
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
17
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
18
Sodium citrate Approved, Investigational Phase 4 68-04-2
19
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 23925 27284
20
Iron isomaltoside 1000 Approved, Investigational Phase 4 1370654-58-2
21
Dexlansoprazole Approved, Investigational Phase 4 103577-45-3, 138530-94-6 9578005
22
Clarithromycin Approved Phase 4 81103-11-9 84029
23
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
24
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
25
Tinidazole Approved, Investigational Phase 4 19387-91-8 5479
26
Ofloxacin Approved Phase 4 82419-36-1 4583
27
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
28
Azithromycin Approved Phase 4 83905-01-5 447043 55185
29
Capecitabine Approved, Investigational Phase 4 154361-50-9 60953
30
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 54670067 5785
31
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 4 303-98-0 5281915
32
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
33
Tyrosine Approved, Investigational, Nutraceutical Phase 4 60-18-4 6057
34
Ecabet Investigational Phase 4 33159-27-2, 86408-72-2 65781
35
Doxifluridine Investigational Phase 4 3094-09-5
36
Furazolidone Experimental, Vet_approved Phase 4 67-45-8 3435 5323714
37 Cyclooxygenase Inhibitors Phase 4
38 Antioxidants Phase 4
39 Respiratory System Agents Phase 4
40 Fibrinolytic Agents Phase 4
41 Antipyretics Phase 4
42 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
43 Parenteral Nutrition Solutions Phase 4
44 Purinergic P2Y Receptor Antagonists Phase 4
45 Purinergic P2 Receptor Antagonists Phase 4
46 Fat Emulsions, Intravenous Phase 4
47 Soy Bean Phase 4
48 Soybean oil, phospholipid emulsion Phase 4
49 Viscum album peptide Phase 4
50 European Mistletoe Phase 4

Interventional clinical trials:

(show top 50) (show all 1997)
# Name Status NCT ID Phase Drugs
1 Phase IV Multi-Institutional Randomized Trial of Capecitabine Plus Oxaliplatin With Bevacizumab in Patients With Potentially Resectable Gastric Cancer With Liver Metastasis Unknown status NCT01962376 Phase 4 Oxaliplatin;Capecitabine;Oxaliplatin;Capecitabine;Bevacizumab
2 Irinotecan Plus Thalidomide in Second Line Advanced Gastric Cancer : A Multicenter, Randomized, Controlled and Prospective Trial Unknown status NCT02401971 Phase 4 Thalidomide;CPT-11
3 Phase IV Multi-Institutional Randomized Trial of Capecitabine Plus Oxaliplatin With Herceptin in Patients With Potentially Resectable HER-2 Positive Gastric Cancer With Liver Metastasis Unknown status NCT02380131 Phase 4 Oxaliplatin plus Capecitabine;Herceptin
4 Effects of Ilaprazole 20mg on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone Endoscopic Submucosal Dissection(ESD) for Gastric Adenoma or Early Gastric Cancer. Unknown status NCT02638584 Phase 4 Ilaprazole;Rabeprazole
5 A Clinical Trial of Maintenance Treatment of Apatinib in Advanced Gastric Cancer Patients Have Completed Postoprative Adjuvant Chemotherapy Unknown status NCT02776527 Phase 4 Apatinib Mesylate Tablets
6 Randomized Controlled Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Unknown status NCT01038154 Phase 4 Pravastatin
7 The CHOLEGAS Study: Multicentric Randomized, Double-Blinded, Controlled Trial of Gastrectomy Plus Prophylactic Cholecystectomy Versus Gastrectomy Only, in Adults Submitted to Gastric Cancer Surgery With Curative Intent. Unknown status NCT00757640 Phase 4
8 An Pilot Study to Assess the Efficacy of Intravenous Iron Isomaltoside 1000 (Monofer®) in the Management of Anaemia Associated With the Palliative Management of Oesophagogastric Adenocarcinoma Unknown status NCT01927328 Phase 4 Iron isomaltoside 1000
9 Fast-track Surgery Recovery Program With Early Jejunostomy Nutrition Protocol Minimizes Time to Adjuvant Chemotherapy in Patients Undergoing Laparoscopic Gastrectomy for Gastric Cancer Unknown status NCT01766765 Phase 4
10 Efficacy of Perioperative Application of Omega-3 Polyunsaturated Fatty Acids on Postoperative Immunization in Gastric Cancer Patients - A Prospective, Randomized Clinical Trial Unknown status NCT01910948 Phase 4 omega-3 polyunsaturated fatty acids
11 An Open Label, Single Group Assigned, Multicenter Study of Apatinib in Patients With Chemo-refractory Advanced or Metastatic Adenocarcinoma of Stomach or Gastroesophageal Junction Unknown status NCT02426034 Phase 4 Apatinib
12 Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD? Unknown status NCT01621451 Phase 4 aspirin and/or clopidogrel;aspirin and/or clopidogrel
13 A Comparison of pCLE Based Targeted Biopsy and WLE Based Standard Biopsy in Staging the Operative Link on Gastric Intestinal Metaplasia (OLGIM): A Randomized，Cross-over Study Unknown status NCT02930616 Phase 4
14 Effect of Helicobacter Pylori on the Availability of Vitamin E and C Unknown status NCT00303160 Phase 4 vitamin C & E supplements
15 Study of the Relationship Between the Rate of Residual Platinum in the Blood and the Incidence of Persistent Neurotoxicity in Patients Treated for Gastrointestinal Cancer With Oxaliplatin Unknown status NCT00274885 Phase 4 oxaliplatin
16 Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment Unknown status NCT03139253 Phase 4 amoxicillin;clarithromycin;tinidazole;levofloxacin;furazolidone;tetracycline;Ilaprazole
17 Randomized Clinical Trial of Omega-3 Fatty Acid-supplemented Parenteral Nutrition Versus Standard Parenteral Nutrition in Patients Undergoing Major Laparoscopic Abdominal Surgery Unknown status NCT01819961 Phase 4 MCT/LCT and fish oil;MCT/LCT
18 Esomeprazole or Famotidine in the Management of Aspirin Related Non-ulcer Dyspepsia - a Double Blind Randomized Control Study Unknown status NCT00978159 Phase 4 esomeprazole;Famotidine
19 In Vivo Inhibition Profile of CYP2C9 by Pineapple Juice Unknown status NCT01649492 Phase 4
20 Efficacy of an Ecabet Sodium and Proton Pump Inhibitor (PPI) Combination Therapy in the Treatment of Iatrogenic Ulcer After Endoscopic Submucosal Dissection: A Prospective Randomized Controlled Trial Unknown status NCT01308177 Phase 4 Ecabet
21 Conventional Fluorescein Sodium Dosage o.1ml/kg Compared With a Lower Fluorescein Sodium Dosage o.02ml/kg for the Detection of Gastric Intestinal Metaplasia in a High Risk Population: a Randomized Controlled Trial Unknown status NCT02534818 Phase 4 lower fluorescein sodium dosage 0.02ml/kg;conventional fluorescein sodium dosage 0.1ml/kg
22 Combined Use of Etomidate and Propofol in Painless Gastroscopy, a Multiple Center, Double Blinded, Randomized,Controled Study. Unknown status NCT01913054 Phase 4 Fentanyl Injection;Etomidate Fat Emulsion Injection;Propofol Injection
23 Efficacy of Two Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment Unknown status NCT02988089 Phase 4 Clarithromycin susceptibility dependant strategy;2 susceptible antibiotics (amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline );proton pump inhibitor (PPI) and Colloidal Bismuth Pectin;amoxicillin and clarithromycin or amoxicillin and furazolidone;amoxicillin and furazolidone or amoxicillin and tetracycline;amoxicillin and furazolidone or amoxicillin and Tinidazole or amoxicillin and Levofloxacin
24 Helicobacter Pylori Eradication Rates of Concomitant Therapy and Tailored Therapy Based on 23S Ribosomal RNA Point Mutations Associated With Clarithromycin Resistance: A Multicenter Prospective Randomized Study Unknown status NCT03130452 Phase 4 Lansoprazole 30mg;Amoxicillin 1.0g Tab;Clarithromycin 500mg;Metronidazole 500 mg
25 Optimizing Influenza Vaccination in Surgical Oncology Patients Unknown status NCT01698177 Phase 4
26 Comparison of the Efficacy of Triple Therapy With or Without Acetylcysteine in the First Line of Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial Unknown status NCT02249546 Phase 4 N-acetylcysteine + PPI-amoxicillin-clarithromycin;PPI-amoxicillin-clarithromycin
27 Phase 4, Prospective, Randomized Study Comparing 14-day Non-bismuth Quadruple "Hybrid" and "Concomitant" Therapies for Helicobacter Pylori Eradication in Settings With High Clarithromycin Resistance Unknown status NCT01464060 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
28 Influence of Immune Nutrition Diet on 90-Day Outcomes in Patients Undergoing Radical Cystectomy and Bladder Substitutions: A Randomized Controlled Trial Unknown status NCT03147586 Phase 4 Bio-tech and omega-3 plus;placebo
29 Prospective Controlled Randomized Comparative Study About Quality of Life (QoL), Immunomodulation and Safety of Adjuvant Mistletoe Treatment in Patients With Gastric Carcinoma Receiving Chemotherapy After Operation Completed NCT01401075 Phase 4 mistletoe extract;doxifluridine
30 Application of Somatostatin for Advanced Gastric Cancer After D2 Lymph Node Dissection —a Prospective Randomized Controlled Study Completed NCT01914692 Phase 4 Somatostatin
31 The Effect of Perioperative Intravenous Magnesium on Pain After Endoscopic Submucosal Dissection for Gastric Neoplasm: Prospective Randomized Double-blind Placebo Controlled Study Completed NCT02235246 Phase 4 Magnesium Sulfate;Normal saline
32 Effectiveness of Premedication With Simethicone or Simethicone Plus N-acetylcysteine vs. Placebo in Improving Visibility During Upper Endoscopy. Completed NCT01653171 Phase 4 Water (Placebo);Simethicone;N-acetylcysteine 500 mg;N-acetylcysteine 1000 mg
33 The Effects of Intraoperative Dexmedetomidine Infusion on Postoperative Bowel Movement in Patients Undergoing Laparoscopic Gastrectomy Completed NCT02164448 Phase 4 the dexmedetomidine group;the control group
34 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
35 Improving Complete Endoscopic Mucosal Resection (EMR) of Colorectal Neoplasia: A Randomized Prospective Comparison of Snares and Injectate in the Resection of Large Sessile Colonic Polyps Completed NCT01471756 Phase 4
36 Comparison of the Effects of Continuous Epidural Analgesia and Continuous Intravenous Analgesia on Postoperative Bowel Movement in Patients Undergoing Laparoscopic Gastrectomy Completed NCT02458573 Phase 4
37 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
38 ONCOXIN® and Quality of Life in Cancer Patients in a Real World Setting Study Completed NCT03550482 Phase 4
39 Comparison of the Analgesic Effect Between Intrathecal Morphine and IV-fentanyl Patient Controlled Analgesia (ITM-IVPCA) and Epidural PCA (PCEA) in Patients Undergoing Gastrectomy -Randomized Allocation Study- Completed NCT01234272 Phase 4 morphine;Ropivacaine
40 A Randomized, Controlled, Double-blind Trial of the Efficacy and Safety of CO2 vs Room Air Insufflation During ESD for Gastric Tumor Completed NCT01579071 Phase 4
41 Standard and Immunostimulating Enteral Nutrition in Patients After Extended Gastrointestinal Surgery - A Prospective, Randomized, Controlled Clinical Trial Completed NCT00576940 Phase 4 Reconvan;Peptisorb
42 Intraluminal Therapy for Helicobacter Pylori Infection Completed NCT03124420 Phase 4 Lansoprazole;Amoxicillin;Clarithromycin
43 Sequential Versus Concomitant Therapy for Helicobacter Pylori Infection Completed NCT00656968 Phase 4 10-day sequential treatment;10-day concomitant therapy
44 Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan Completed NCT03524833 Phase 4 Metronidazole;Lansoprazole, Amoxicillin, Metronidazole
45 Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan Completed NCT03521726 Phase 4 Amoxicillin;Rabeprazole, Amoxicillin
46 Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan Completed NCT03516669 Phase 4 Clarithromycin;Amoxicillin, Clarithromycin
47 The Efficacy of Sequential Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection - A Pilot Study Completed NCT00885417 Phase 4 Cravit-based sequential therapy
48 Effect of H. Pylori Eradication on the Fate of H. Pylori-associated Gastric Polyp (Randomized Controlled Study) Completed NCT03065868 Phase 4 H. pylori eradication (Amoxaxillin, Lanston, Clarithromycin)
49 Whether 18F-ALF-NOTA-PRGD2 PET/CT Scan Can Predict the Efficacy and Adverse Events of Apatinib in Patients With Malignancies. Completed NCT03384511 Phase 4 Apatinib
50 Phase IV Study Comparing the Duration of Sequential Therapy Completed NCT01042184 Phase 4 Sequential therapy for 14 days;Sequential therapy for 10 days;Triple therapy for 14 days

Search NIH Clinical Center for Gastric Cancer

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Capecitabine
Cisplatin
Cisplatin
CISPLATIN PWDR
docetaxel
Doxorubicin
Floxuridine
Fluorouracil
Fluorouracil
Ifosfamide
irinotecan
Irinotecan
Irinotecan hydrochloride
Methotrexate
Methotrexate Sodium
Oxaliplatin
Paclitaxel

Cochrane evidence based reviews: stomach neoplasms

Sources

Genetic Tests for Gastric Cancer

About this section

Genetic tests related to Gastric Cancer:

# Genetic test Affiliating Genes
1 Stomach Cancer 29
Sources

Anatomical Context for Gastric Cancer

About this section

MalaCards organs/tissues related to Gastric Cancer:

41
Lymph Node, Liver, Testes, Lung, Breast, Colon, Bone

The Foundational Model of Anatomy Ontology organs/tissues related to Gastric Cancer:

19
Stomach
Sources

Publications for Gastric Cancer

About this section

Articles related to Gastric Cancer:

(show top 50) (show all 38616)
# Title Authors PMID Year
1
Genetic alterations of the MYH gene in gastric cancer. 9 38 8 71
15273732 2004
2
Inactivating mutations of the caspase-10 gene in gastric cancer. 9 38 8 71
11973654 2002
3
Functionally inactivating point mutation in the tumor-suppressor IRF-1 gene identified in human gastric cancer. 9 38 8 71
9679752 1998
4
Genetic alterations of the KLF6 gene in gastric cancer. 38 8 71
15824733 2005
5
The APC gene, responsible for familial adenomatous polyposis, is mutated in human gastric cancer. 38 8 71
1317264 1992
6
Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. 9 38 8
18488030 2008
7
Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. 9 38 8
11419427 2001
8
Microsatellite instability and mutations of p53 and TGF-beta RII genes in gastric cancer. 9 38 8
8882883 1996
9
Analysis for microsatellite instability and mutations of the DNA mismatch repair gene hMLH1 in familial gastric cancer. 9 38 8
8938136 1996
10
Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. 38 71
23852704 2014
11
miR-21 plays a pivotal role in gastric cancer pathogenesis and progression. 9 38 88
18794849 2008
12
E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. 9 38 88
18328430 2008
13
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. 9 71
15608678 2005
14
A full genome scan for gastric cancer. 38 8
15635081 2005
15
Gastric cancer originating from bone marrow-derived cells. 38 8
15567866 2004
16
Genetic susceptibility and gastric cancer risk. 38 8
12115538 2002
17
Red meat, family history, and increased risk of gastric cancer with microsatellite instability. 38 8
11454685 2001
18
Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. 9 71
11325814 2001
19
Interleukin-1 polymorphisms associated with increased risk of gastric cancer. 38 8
10746728 2000
20
Familial gastric cancer: overview and guidelines for management. 38 8
10593993 1999
21
Familial gastric cancer in the Japanese population is frequently located at the cardiac region. 38 8
10436415 1999
22
Genetic predisposition to gastric cancer. 38 8
10209666 1999
23
Clinicopathologic significance of the K-ras gene codon 12 point mutation in stomach cancer. An analysis of 140 cases. 38 71
7773929 1995
24
Family history and the risk of stomach and colorectal cancer. 38 8
1606546 1992
25
Familial occurrence of gastric cancer in the 2-year experience of a population-based registry. 38 8
2224804 1990
26
Helicobacter gastritis and intestinal metaplasia in a gastric cancer family. 38 8
1969086 1990
27
The decline in gastric cancer: epidemiology of an unplanned triumph. 38 8
3533579 1986
28
Clinicopathologic parameters associated with the FDG-avidity in staging of early gastric cancer using 18F-FDG PET. 38 17
31374056 2019
29
Postoperative intraperitoneal hyperthermic perfusion improve survival for advanced gastric cancer. 38 17
31348304 2019
30
PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours. 71
26266975 2015
31
Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity. 71
26266985 2015
32
Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly. 71
23100325 2013
33
Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome. 71
22683711 2012
34
Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. 71
22658544 2012
35
Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. 71
22729222 2012
36
De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. 71
22729223 2012
37
De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. 71
22729224 2012
38
Keratinocytic epidermal nevi are associated with mosaic RAS mutations. 71
22499344 2012
39
Somatic KRAS mutations associated with a human nonmalignant syndrome of autoimmunity and abnormal leukocyte homeostasis. 71
21079152 2011
40
A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. 38 88
21112772 2011
41
MicroRNA-192 and -215 are upregulated in human gastric cancer in vivo and suppress ALCAM expression in vitro. 38 88
21119604 2011
42
Inhibitory effects of miRNA-200c on chemotherapy-resistance and cell proliferation of gastric cancer SGC7901/DDP cells. 38 88
21114921 2010
43
Mosaicism for oncogenic G12D KRAS mutation associated with epidermal nevus, polycystic kidneys and rhabdomyosarcoma. 71
20805368 2010
44
Discordance for Schimmelpenning-Feuerstein-Mims syndrome in monochorionic twins supports the concept of a postzygotic mutation. 71
20949522 2010
45
Epigenetic regulation of miR-196b expression in gastric cancer. 38 88
20662076 2010
46
Hsa-mir-27a genetic variant contributes to gastric cancer susceptibility through affecting miR-27a and target gene expression. 38 88
20666778 2010
47
Short rare MUC6 minisatellites-5 alleles influence susceptibility to gastric carcinoma by regulating gene. 8
20506113 2010
48
MiR-150 promotes gastric cancer proliferation by negatively regulating the pro-apoptotic gene EGR2. 38 88
20067763 2010
49
Functional links between clustered microRNAs: suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer. 38 88
19153141 2009
50
MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin. 9 88
18789835 2009
Sources

Variations for Gastric Cancer

About this section

ClinVar genetic disease variations for Gastric Cancer:

6 (show top 50) (show all 92)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 FGFR2 NM_000141.4(FGFR2): c.314A> G (p.Tyr105Cys) single nucleotide variant Pathogenic rs1434545235 10:123325014-123325014 10:121565500-121565500
2 APC NM_000038.6(APC): c.3867T> A (p.Cys1289Ter) single nucleotide variant Pathogenic rs1554085355 5:112175158-112175158 5:112839461-112839461
3 MUTYH NM_001128425.1(MUTYH): c.1213C> T (p.Pro405Ser) single nucleotide variant Pathogenic rs121908382 1:45797202-45797202 1:45331530-45331530
4 MUTYH NM_001128425.1(MUTYH): c.1241A> G (p.Gln414Arg) single nucleotide variant Pathogenic rs121908383 1:45797174-45797174 1:45331502-45331502
5 KLF6 NM_001300.6(KLF6): c.465C> A (p.Ser155Arg) single nucleotide variant Pathogenic rs121909144 10:3824044-3824044 10:3781852-3781852
6 CASP10 NM_032977.3(CASP10): c.769C> T (p.Gln257Ter) single nucleotide variant Pathogenic rs121909775 2:202070652-202070652 2:201205929-201205929
7 CASP10 NM_032977.3(CASP10): c.440T> C (p.Met147Thr) single nucleotide variant Pathogenic rs121909776 2:202052521-202052521 2:201187798-201187798
8 KRAS NM_004985.5(KRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs121913530 12:25398285-25398285 12:25245351-25245351
9 FGFR2 NM_000141.4(FGFR2): c.1025G> A (p.Cys342Tyr) single nucleotide variant Pathogenic rs121918487 10:123276892-123276892 10:121517378-121517378
10 FGFR2 NM_000141.4(FGFR2): c.1032G> A (p.Ala344=) single nucleotide variant Pathogenic rs121918491 10:123276885-123276885 10:121517371-121517371
11 FGFR2 NM_000141.4(FGFR2): c.755C> G (p.Ser252Trp) single nucleotide variant Pathogenic rs79184941 10:123279677-123279677 10:121520163-121520163
12 FGFR2 NM_000141.4(FGFR2): c.758C> G (p.Pro253Arg) single nucleotide variant Pathogenic rs77543610 10:123279674-123279674 10:121520160-121520160
13 FGFR2 NM_000141.4(FGFR2): c.1124A> G (p.Tyr375Cys) single nucleotide variant Pathogenic rs121913478 10:123274794-123274794 10:121515280-121515280
14 FGFR2 NM_000141.4(FGFR2): c.799T> C (p.Ser267Pro) single nucleotide variant Pathogenic rs121918505 10:123279633-123279633 10:121520119-121520119
15 PIK3CA NM_006218.4(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 3:178952085-178952085 3:179234297-179234297
16 MUTYH NM_001128425.1(MUTYH): c.536A> G (p.Tyr179Cys) single nucleotide variant Pathogenic rs34612342 1:45798475-45798475 1:45332803-45332803
17 PIK3CA NM_006218.4(PIK3CA): c.3203dup (p.Asn1068fs) duplication Pathogenic rs587776802 3:178952148-178952148 3:179234360-179234360
18 IRF1 NM_002198.3(IRF1): c.22A> T (p.Met8Leu) single nucleotide variant Pathogenic rs121912469 5:131825149-131825149 5:132489457-132489457
19 PIK3CA NM_006218.4(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic rs121913281 3:178952084-178952084 3:179234296-179234296
20 APC NM_000038.6(APC): c.637C> T (p.Arg213Ter) single nucleotide variant Pathogenic rs587781392 5:112116592-112116592 5:112780895-112780895
21 MUTYH NM_001128425.1(MUTYH): c.55C> T (p.Arg19Ter) single nucleotide variant Pathogenic rs587780088 1:45800165-45800165 1:45334493-45334493
22 APC NM_000038.6(APC): c.847C> T (p.Arg283Ter) single nucleotide variant Pathogenic rs786201856 5:112151204-112151204 5:112815507-112815507
23 APC NM_000038.6(APC): c.646C> T (p.Arg216Ter) single nucleotide variant Pathogenic rs62619935 5:112128143-112128143 5:112792446-112792446
24 APC NM_000038.6(APC): c.694C> T (p.Arg232Ter) single nucleotide variant Pathogenic rs397515734 5:112128191-112128191 5:112792494-112792494
25 KRAS NM_004985.5(KRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic rs121913529 12:25398284-25398284 12:25245350-25245350
26 APC NM_000038.6(APC): c.2805C> A (p.Tyr935Ter) single nucleotide variant Pathogenic rs137854575 5:112174096-112174096 5:112838399-112838399
27 APC NM_000038.6(APC): c.1660C> T (p.Arg554Ter) single nucleotide variant Pathogenic rs137854573 5:112164586-112164586 5:112828889-112828889
28 APC NM_000038.6(APC): c.3199C> T (p.Gln1067Ter) single nucleotide variant Pathogenic rs137854571 5:112174490-112174490 5:112838793-112838793
29 APC NM_000038.6(APC): c.3359G> A (p.Gly1120Glu) single nucleotide variant Pathogenic rs28933379 5:112174650-112174650 5:112838953-112838953
30 FGFR2 NM_000141.4(FGFR2): c.1150G> A (p.Gly384Arg) single nucleotide variant Pathogenic rs1554927408 10:123274768-123274768 10:121515254-121515254
31 APC NM_000038.6(APC): c.933+1G> A single nucleotide variant Pathogenic/Likely pathogenic rs876660765 5:112151291-112151291 5:112815594-112815594
32 APC NM_000038.6(APC): c.1312+3A> G single nucleotide variant Pathogenic/Likely pathogenic rs863225311 5:112155044-112155044 5:112819347-112819347
33 APC NM_000038.6(APC): c.70C> T (p.Arg24Ter) single nucleotide variant Pathogenic/Likely pathogenic rs145945630 5:112090657-112090657 5:112754960-112754960
34 MUTYH NM_001128425.1(MUTYH): c.734G> A (p.Arg245His) single nucleotide variant Pathogenic/Likely pathogenic rs140342925 1:45798117-45798117 1:45332445-45332445
35 MUTYH NM_001128425.1(MUTYH): c.389-1G> C single nucleotide variant Pathogenic/Likely pathogenic rs372267274 1:45798843-45798843 1:45333171-45333171
36 MUTYH NM_001128425.1(MUTYH): c.1187-2A> G single nucleotide variant Pathogenic/Likely pathogenic rs587781628 1:45797230-45797230 1:45331558-45331558
37 ERBB2 NM_004448.3(ERBB2): c.2326G> A (p.Gly776Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28933369 17:37880997-37880997 17:39724744-39724744
38 MUTYH NM_001128425.1(MUTYH): c.1187G> A (p.Gly396Asp) single nucleotide variant Pathogenic/Likely pathogenic rs36053993 1:45797228-45797228 1:45331556-45331556
39 PIK3CA NM_006218.4(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 3:178936091-178936091 3:179218303-179218303
40 FGFR2 NM_000141.4(FGFR2): c.1013G> A (p.Gly338Glu) single nucleotide variant Pathogenic/Likely pathogenic rs1057519044 10:123276904-123276904 10:121517390-121517390
41 CTNNB1 NM_001904.4(CTNNB1): c.110C> A (p.Ser37Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913403 3:41266113-41266113 3:41224622-41224622
42 ERBB3 NM_001982.3(ERBB3): c.850G> A (p.Gly284Arg) single nucleotide variant Likely pathogenic rs1057519803 12:56481922-56481922 12:56088138-56088138
43 NRAS NM_002524.5(NRAS): c.37G> A (p.Gly13Ser) single nucleotide variant Likely pathogenic rs121434595 1:115258745-115258745 1:114716124-114716124
44 CTNNB1 NM_001904.4(CTNNB1): c.109T> C (p.Ser37Pro) single nucleotide variant Likely pathogenic rs121913228 3:41266112-41266112 3:41224621-41224621
45 CTNNB1 NM_001904.4(CTNNB1): c.118A> G (p.Thr40Ala) single nucleotide variant Likely pathogenic rs1057519836 3:41266121-41266121 3:41224630-41224630
46 MUTYH NM_001128425.1(MUTYH): c.1229_1230dup (p.Pro411fs) duplication Likely pathogenic rs1553125914 1:45797186-45797187 1:45331514-45331515
47 MTHFR NM_005957.4(MTHFR): c.665C> T (p.Ala222Val) single nucleotide variant drug response rs1801133 1:11856378-11856378 1:11796321-11796321
48 APC NM_000038.6(APC): c.8389A> G (p.Ser2797Gly) single nucleotide variant Conflicting interpretations of pathogenicity rs147287751 5:112179680-112179680 5:112843983-112843983
49 APC NM_000038.6(APC): c.6639G> A (p.Met2213Ile) single nucleotide variant Conflicting interpretations of pathogenicity rs35540155 5:112177930-112177930 5:112842233-112842233
50 APC NM_000038.6(APC): c.95A> G (p.Asn32Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs539108537 5:112090682-112090682 5:112754985-112754985

UniProtKB/Swiss-Prot genetic disease variations for Gastric Cancer:

74 (show all 19)
# Symbol AA change Variation ID SNP ID
1 APC p.Gly817Cys VAR_005035
2 APC p.Ile880Thr VAR_005036 rs140029598
3 APC p.Asn942Asp VAR_005039
4 APC p.Gly1120Glu VAR_005042 rs28933379
5 APC p.Arg1171His VAR_005043 rs372481703
6 APC p.Phe1197Ser VAR_005045
7 APC p.Ile1259Thr VAR_005046
8 APC p.Gly1312Glu VAR_005050
9 APC p.Val1326Ala VAR_005052
10 CASP10 p.Met147Thr VAR_037428 rs121909776
11 IRF1 p.Met8Leu VAR_065134 rs121912469
12 IRF1 p.Trp11Arg VAR_065135 rs121912470
13 KRAS p.Gly12Val VAR_006840 rs121913529
14 KRAS p.Gly12Asp VAR_016026 rs121913529
15 KRAS p.Gly12Ser VAR_016028 rs121913530
16 KRAS p.Gly13Asp VAR_016029 rs112445441
17 KRAS p.Ala59Thr VAR_016030 rs121913528
18 KRAS p.Lys5Asn VAR_064849 rs104894361
19 MUTYH p.Pro402Ser VAR_026049 rs121908382

Cosmic variations for Gastric Cancer:

9 (show top 50) (show all 18186)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM5575790 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.1159G>A p.A387T 18:25226759-25226759 69
2 COSM5576102 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.443G>A p.C148Y 18:25227475-25227475 69
3 COSM5576231 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.3434T>G p.V1145G 18:25224484-25224484 69
4 COSM5575704 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.2285G>A p.R762H 18:25225633-25225633 69
5 COSM5576098 ZNF384 stomach,NS,carcinoma,adenocarcinoma c.1136G>A p.R379Q 12:6669044-6669044 69
6 COSM3732832 ZNF341 stomach,NS,carcinoma,adenocarcinoma c.2512G>A p.A838T 20:33791485-33791485 69
7 COSM6964818 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.5929G>C p.G1977R 16:72796753-72796753 69
8 COSM6953000 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.4553G>T p.G1518V 16:72798129-72798129 69
9 COSM6965918 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.795C>A p.D265E 16:72959351-72959351 69
10 COSM6826469 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.1858C>T p.H620Y 16:72958288-72958288 69
11 COSM6941990 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.1081G>A p.G361R 16:72959065-72959065 69
12 COSM6986594 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.8198G>T p.R2733L 16:72794484-72794484 69
13 COSM6934198 YES1 stomach,NS,carcinoma,adenocarcinoma c.350G>A p.R117K 18:751726-751726 69
14 COSM6944960 YAP1 stomach,NS,carcinoma,adenocarcinoma c.356C>G p.T119S 11:102114178-102114178 69
15 COSM6951579 XRCC2 stomach,NS,carcinoma,adenocarcinoma c.140A>G p.H47R 7:152649345-152649345 69
16 COSM7346483 XPO1 stomach,NS,carcinoma,adenocarcinoma c.781C>T p.R261* 2:61496986-61496986 69
17 COSM7346537 XPO1 stomach,NS,carcinoma,adenocarcinoma c.3154C>T p.R1052C 2:61478882-61478882 69
18 COSM7346883 XPO1 stomach,NS,carcinoma,adenocarcinoma c.1249C>T p.R417C 2:61493050-61493050 69
19 COSM5576197 XPO1 stomach,NS,carcinoma,adenocarcinoma c.479G>A p.S160N 2:61499824-61499824 69
20 COSM1022124 XPO1 stomach,NS,carcinoma,adenocarcinoma c.382G>A p.G128R 2:61502022-61502022 69
21 COSM7346676 WT1 stomach,NS,carcinoma,adenocarcinoma c.1199C>T p.T400I 11:32392001-32392001 69
22 COSM185632 WT1 stomach,NS,carcinoma,adenocarcinoma c.869C>T p.T290M 11:32399973-32399973 69
23 COSM7346682 WT1 stomach,NS,carcinoma,adenocarcinoma c.1195A>T p.K399* 11:32392005-32392005 69
24 COSM7346455 WT1 stomach,NS,carcinoma,adenocarcinoma c.787G>A p.G263R 11:32416500-32416500 69
25 COSM3935439 WT1 stomach,NS,carcinoma,adenocarcinoma c.961C>T p.R321C 11:32396341-32396341 69
26 COSM926359 WT1 stomach,NS,carcinoma,adenocarcinoma c.1298G>A p.R433H 11:32389110-32389110 69
27 COSM6906958 WT1 stomach,NS,carcinoma,adenocarcinoma c.122C>T p.A41V 11:32435020-32435020 69
28 COSM7346679 WT1 stomach,NS,carcinoma,adenocarcinoma c.1201C>T p.H401Y 11:32391999-32391999 69
29 COSM7346688 WT1 stomach,NS,carcinoma,adenocarcinoma c.1172A>T p.K391M 11:32392028-32392028 69
30 COSM7346685 WT1 stomach,NS,carcinoma,adenocarcinoma c.1188C>G p.D396E 11:32392012-32392012 69
31 COSM7346839 WT1 stomach,NS,carcinoma,adenocarcinoma c.1199C>G p.T400S 11:32392001-32392001 69
32 COSM20570 WEE2 stomach,NS,carcinoma,adenocarcinoma c.996C>G p.N332K 7:141723249-141723249 69
33 COSM3732971 USH2A stomach,NS,carcinoma,adenocarcinoma c.8488A>T p.I2830F 1:215878834-215878834 69
34 COSM3732707 USH2A stomach,NS,carcinoma,adenocarcinoma c.140A>T p.K47M 1:216422197-216422197 69
35 COSM3732771 USH2A stomach,NS,carcinoma,adenocarcinoma c.11815G>A p.E3939K 1:215728281-215728281 69
36 COSM3732767 USH2A stomach,NS,carcinoma,adenocarcinoma c.11734G>A p.E3912K 1:215728362-215728362 69
37 COSM3732855 USH2A stomach,NS,carcinoma,adenocarcinoma c.11927C>T p.T3976M 1:215728169-215728169 69
38 COSM1094394 UBR5 stomach,NS,carcinoma,adenocarcinoma c.5561G>A p.R1854H 8:102285262-102285262 69
39 COSM5575712 UBR5 stomach,NS,carcinoma,adenocarcinoma c.5261G>A p.R1754Q 8:102285736-102285736 69
40 COSM6928622 U2AF1 stomach,NS,carcinoma,adenocarcinoma c.68A>G p.K23R 21:43104379-43104379 69
41 COSM3793896 TSHR stomach,NS,carcinoma,adenocarcinoma c.909G>C p.E303D 14:81142967-81142967 69
42 COSM6949448 TSHR stomach,NS,carcinoma,adenocarcinoma c.256G>A p.D86N 14:81068267-81068267 69
43 COSM6810259 TSC2 stomach,NS,carcinoma,adenocarcinoma c.2296G>A p.V766M 16:2072924-2072924 69
44 COSM5363694 TSC2 stomach,NS,carcinoma,adenocarcinoma c.2314G>A p.A772T 16:2072942-2072942 69
45 COSM6918762 TSC2 stomach,NS,carcinoma,adenocarcinoma c.3599G>A p.R1200Q 16:2080366-2080366 69
46 COSM6505728 TSC2 stomach,NS,carcinoma,adenocarcinoma c.5377C>T p.R1793W 16:2088563-2088563 69
47 COSM5576247 TSC2 stomach,NS,carcinoma,adenocarcinoma c.2803G>T p.A935S 16:2076551-2076551 69
48 COSM6922577 TSC2 stomach,NS,carcinoma,adenocarcinoma c.3820T>C p.S1274P 16:2082441-2082441 69
49 COSM5575753 TSC2 stomach,NS,carcinoma,adenocarcinoma c.2357G>A p.R786H 16:2074201-2074201 69
50 COSM6921200 TSC2 stomach,NS,carcinoma,adenocarcinoma c.445A>G p.N149D 16:2054404-2054404 69

Copy number variations for Gastric Cancer from CNVD:

7 (show top 50) (show all 694)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13401 1 1 2300000 Gain SLC35E2 Gastric cancer
2 13782 1 1 39600000 Gain LCK Gastric cancer
3 13783 1 1 39600000 Gain MDS2 Gastric cancer
4 13784 1 1 39600000 Gain PAX7 Gastric cancer
5 13785 1 1 39600000 Gain PRDM16 Gastric cancer
6 13786 1 1 39600000 Gain RPL22 Gastric cancer
7 13787 1 1 39600000 Gain SDHB Gastric cancer
8 13988 1 102200000 107200000 Loss AMY1A Gastric cancer
9 13989 1 102200000 107200000 Loss AMY2A Gastric cancer
10 19425 1 150222010 150233338 Amplification S100A10 Gastric cancer
11 22648 1 168031174 168088853 Amplification C1orf112 Gastric cancer
12 22794 1 168899937 168975165 Amplification PRRX1 Gastric cancer
13 24343 1 178867796 179122103 Amplification XPR1 Gastric cancer
14 25997 1 195319997 195382287 Amplification ASPM Gastric cancer
15 26293 1 198787930 198856485 Amplification KIF14 Gastric cancer
16 27965 1 216525252 216577948 Amplification RRP15 Gastric cancer
17 28583 1 223655827 223682407 Amplification LBR Gastric cancer
18 29302 1 2300000 5400000 Gain TP73 Gastric cancer
19 29303 1 2300000 5400000 Gain WDR8 Gastric cancer
20 29725 1 234780594 234834437 Amplification HEATR1 Gastric cancer
21 30108 1 240078158 240119671 Amplification EXO1 Gastric cancer
22 30593 1 244770489 244796186 Amplification TFB2M Gastric cancer
23 37702 1 938709 939782 Copy number G1P2 Gastric cancer
24 37787 1 94700000 99700000 Loss DPYD Gastric cancer
25 38140 10 1 135006516 Loss Gastric cancer
26 40043 10 123336181 123337713 Amplification FGFR2 Gastric cancer
27 40401 10 127500000 130600000 Gain Gastric cancer
28 41839 10 24600000 135534747 Loss Gastric cancer
29 45622 10 73000000 81800000 Amplification PSAP Gastric cancer
30 48318 11 1 135006516 Gain Gastric cancer
31 49710 11 110400000 130800000 Gain Gastric cancer
32 49997 11 112500000 130800000 Gain Gastric cancer
33 53360 11 2800000 10700000 Gain CDKN1C Gastric cancer
34 53361 8 145646122 145661839 Gain CYHR1 Gastric cancer
35 53362 8 145669924 145672526 Gain FOXH1 Gastric cancer
36 53363 11 2800000 10700000 Gain KCNQ1 Gastric cancer
37 53364 11 2800000 10700000 Gain KCNQ1DN Gastric cancer
38 53365 8 145662545 145670307 Gain KIFC2 Gastric cancer
39 53366 11 2800000 10700000 Gain SLC22A18 Gastric cancer
40 53367 11 2800000 10700000 Gain SLC22A1LS Gastric cancer
41 54234 11 40200000 42900000 Amplification LRRC4C Gastric cancer
42 56156 11 57265297 57267459 Copy number SELH Gastric cancer
43 56517 11 59900000 61700000 Gain PGA5 Gastric cancer
44 58503 11 68100000 70400000 Amplification CCND1 Gastric cancer
45 58504 11 68100000 70400000 Amplification FGF3 Gastric cancer
46 58651 11 69161019 69306967 Amplification CCND1 Gastric cancer
47 58653 11 69161019 69306967 Amplification FGF19 Gastric cancer
48 58655 11 69161019 69306967 Amplification FGF4 Gastric cancer
49 58657 11 69161019 69306967 Amplification ORAOV1 Gastric cancer
50 59248 11 73719009 73787150 Amplification PGM2L1 Gastric cancer
Sources

Expression for Gastric Cancer

About this section
Search GEO for disease gene expression data for Gastric Cancer.
Sources

Pathways for Gastric Cancer

About this section

Pathways related to Gastric Cancer according to KEGG:

37
# Name Kegg Source Accession
1 Gastric cancer hsa05226

Pathways related to Gastric Cancer according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
PI3K-Akt signaling pathway 37
Show member pathways
 12.84 PIK3CA KRAS IRF1 FGFR2 ERBB2 CTNNB1
2
Endometrial cancer 37
Show member pathways
 12.76 PIK3CA KRAS FGFR2 ERBB2 CTNNB1 APC
3
Pathways in cancer 37
12.71 PIK3CA KRAS FGFR2 ERBB2 CTNNB1 APC
4
Gastric cancer 37
Show member pathways
 12.62 PIK3CA KRAS FGFR2 ERBB2 CTNNB1 APC
5
Development HGF signaling pathway 22
Show member pathways
 12.59 PIK3CA KRAS ERBB2 CTNNB1 APC
6
mTOR signaling pathway (KEGG) 37
Show member pathways
 12.39 PIK3CA KRAS FGFR2 ERBB2 APC
7
Prolactin Signaling Pathway 1 37
Show member pathways
 12.36 PIK3CA KRAS IRF1 ERBB2
8
G-protein signaling RAC1 in cellular process 22
Show member pathways
 12.27 PIK3CA KRAS FGFR2 ERBB2 CTNNB1 APC
9
DNA Damage Response 1
Show member pathways
 12.25 MIR222 MIR221 MIR20A MIR106B
10
Human T-cell leukemia virus 1 infection 37
12.23 PIK3CA KRAS CTNNB1 APC
11
Apoptosis Pathway 71
Show member pathways
 12.22 PIK3CA KRAS FGFR2 ERBB2 CTNNB1 CASP10
12
Proteoglycans in cancer 37
12.14 PIK3CA MIR21 KRAS ERBB2 CTNNB1
13
MAPK Signaling: Mitogen Stimulation Pathway 65
Show member pathways
 12.09 PIK3CA KRAS FGFR2 ERBB2
14
AKT Signaling Pathway 67
12 PIK3CA KRAS FGFR2 ERBB2
15
Signaling pathways regulating pluripotency of stem cells 37
11.91 PIK3CA KRAS FGFR2 CTNNB1 APC
16
MicroRNAs in cancer 37
11.89 PIK3CA MIR34A MIR25 MIR222 MIR221 MIR21
17
TNF signaling pathway 37
11.85 PIK3CA IRF1 CASP10
18
Signaling by ERBB4 66
Show member pathways
 11.83 PIK3CA KRAS ERBB2
19
DNA Damage Response (only ATM dependent) 1
11.72 PIK3CA KRAS ERBB2 CTNNB1 APC
20
VEGF Pathway (Tocris) 61
Show member pathways
 11.68 PIK3CA KRAS CASP10
21
Association Between Physico-Chemical Features and Toxicity Associated Pathways 1
11.58 E